- Home
- YMAB vs CRDF Comparison
YMAB vs CRDF Comparison
Compare YMAB & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- CRDF
- Stock Information
- Founded
- YMAB 2015
- CRDF 1999
- Country
- YMAB United States
- CRDF United States
- Employees
- YMAB N/A
- CRDF N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YMAB Health Care
- CRDF Health Care
- Exchange
- YMAB Nasdaq
- CRDF Nasdaq
- Market Cap
- YMAB 218.4M
- CRDF 196.2M
- IPO Year
- YMAB 2018
- CRDF N/A
- Fundamental
- Price
- YMAB $3.89
- CRDF $2.66
- Analyst Decision
- YMAB Buy
- CRDF Strong Buy
- Analyst Count
- YMAB 11
- CRDF 4
- Target Price
- YMAB $18.73
- CRDF $12.25
- AVG Volume (30 Days)
- YMAB 216.5K
- CRDF 1.1M
- Earning Date
- YMAB 05-13-2025
- CRDF 05-08-2025
- Dividend Yield
- YMAB N/A
- CRDF N/A
- EPS Growth
- YMAB N/A
- CRDF N/A
- EPS
- YMAB N/A
- CRDF N/A
- Revenue
- YMAB $87,685,000.00
- CRDF $587,000.00
- Revenue This Year
- YMAB N/A
- CRDF N/A
- Revenue Next Year
- YMAB $18.83
- CRDF N/A
- P/E Ratio
- YMAB N/A
- CRDF N/A
- Revenue Growth
- YMAB 3.38
- CRDF N/A
- 52 Week Low
- YMAB $3.84
- CRDF $2.01
- 52 Week High
- YMAB $17.47
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- YMAB 40.44
- CRDF 42.40
- Support Level
- YMAB $3.76
- CRDF $2.42
- Resistance Level
- YMAB $4.60
- CRDF $2.87
- Average True Range (ATR)
- YMAB 0.33
- CRDF 0.19
- MACD
- YMAB -0.02
- CRDF 0.01
- Stochastic Oscillator
- YMAB 15.12
- CRDF 27.91
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.